The 2018 ASCO/CAP focused update of the HER2 testing guidelines emphasized the need for parallel assessment of IHC and in situ hybridization (ISH) results in invasive breast carcinoma (IBC) testing. This evidence concerns the gene ERBB2 and invasive breast carcinoma.